Project Grant K08CA290061
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$253K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $514,196 to the Dana-Farber Cancer Institute (DFCI) to investigate IGF2BP1 as a novel therapeutic target for Ewing sarcoma, an aggressive pediatric bone cancer. The key products/services to be delivered under this award include: Using CRISPR-Cas9 genome editing to validate IGF2BP1 as an Ewing sarcoma dependency in cell lines and patient-derived xenograft models. This will include...
The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
The Defense Health Agency awarded Dana-Farber Cancer Institute a $712,001 Project Grant under the Military Medical Research and Development program to conduct research on understanding the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis through integrative computational biology. The three-year award runs from September 1, 2023 through August 31, 2026. Through this funding, Dana-Farber will utilize computational methods to analyze Ewing sarcoma tumor samples and related...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $872,555 to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA over a five-year period from September 1, 2024 to August 31, 2029. The award aims to catalyze long-read cancer genome sequencing efforts through the development of informatic methods for the discovery and characterization of somatic genetic alterations in cancer genomes. Key objectives include improving...
This $523,292 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to investigate the molecular mechanisms by which the microhomology-mediated end-joining (MMEJ) DNA repair pathway is suppressed in Ewing sarcoma (EWS) cancer cells. The research also aims to assess the function of the MMEJ pathway in EWS patient tumor samples and explore therapeutic approaches that exploit this unique DNA repair...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
The National Cancer Institute (NCI) awarded a $593,028 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope, a nonprofit medical research organization. The grant will fund a 5-year research project from April 2025 to March 2030 to investigate the role of IL-6/STAT3 signaling in driving metastasis and immunosuppression in CIC-DUX4 fusion-positive sarcomas, an aggressive and understudied form of pediatric and young adult...
This $1,290,499 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a research project led by the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The project is studying the effect of clonal hematopoiesis on cardiovascular-related outcomes in patients diagnosed with kidney cancer. The four-year research effort, which commenced on September 1, 2023 and is scheduled for completion by August 31, 2027, aims to advance...
The Defense Health Agency has awarded a $1,483,340 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) in Boston, MA. The grant, with a performance period from June 1, 2024 to May 31, 2028, will fund research to harness extracellular domain (ECD) cleavage of anaplastic lymphoma kinase (ALK) for immunotherapy against neuroblastoma. As a non-profit hospital and cancer research center, DFCI will...
The Dana-Farber Cancer Institute, Inc. (DFCI) was awarded a $1,156,892 Project Grant from the Department of the Army Medical Command to utilize cell-free methylomes to inform clinical scenarios in renal cell carcinoma. The grant was awarded on August 15, 2021 with a completion date of August 14, 2024 under the Military Medical Research and Development program (CFDA 12.420). Through this funding, DFCI will apply its work on cell-free methylomes, a non-invasive method to analyze DNA methylation...